News & Media
Diplomat Dispensing Advanced Kidney Treatment, CABOMETYX®
FLINT, Mich. — Jan. 15, 2018 — The nation’s largest independent specialty pharmacy is dispensing CABOMETYX® (cabozantinib) tablets, now with an expanded indication to include first-line therapy for patients with advanced renal cell carcinoma.
Diplomat Pharmacy Inc. (NYSE: DPLO), is dispensing Exelixis’ limited-distribution treatment CABOMETYX® (cabozantinib), now with an expanded indication.
CABOMETYX was recently approved by the Food and Drug Administration as a first-line therapy indicated to treat patients with advanced renal cell carcinoma (RCC). CABOMETYX was initially approved as a second-line therapy for advanced RCC in 2016.
RCC is a type of cancer in which malignant cells form in the lining of tubules of the kidney. According to the American Cancer Society, RCC is the most common form of kidney cancer found in adults, accounting for nearly 90 percent of all kidney cancers.
“In supporting patients with advanced renal cell carcinoma, we are pleased to offer CABOMETYX as a new first-line treatment option,” said Joel Saban, Diplomat president. “CABOMETYX tablets offer an important new alternative for patients seeking therapy options in the first-line setting and beyond.”
CABOMETYX is manufactured by Exelixis, Inc. For full prescribing information, click here.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) is the nation’s largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payers, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.